Multiplex method for measuring biomarkers of Alzheimer disease in cerebrospinal fluid

Clinical Chemistry

Volumn 51, Issue 2, 2005, Pages 289-290

  Miller, Bradley B ^a   Mandell, James W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; GELATINASE B; INTERLEUKIN 6; PROTEIN S100B; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOPSY; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; OVARY CARCINOMA; PHENOTYPE; PREVALENCE; PROTEOMICS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; MICROSPHERES; SENSITIVITY AND SPECIFICITY;

EID: 12944281043     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.044016     Document Type: Editorial

References (12)

1. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 1997;18:S21-6.
2. Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759-66.
3. Markesbery WR. Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S13-9.
4. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123:484-98.
5. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-9.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
7. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003;2:605-13.
8. 181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-45.
9. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004;370:36-9.
10. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003;43:191-6.
11. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004;25:1009-15.
12. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.